Skip to main content

buprenorphine (Sixmo®)

 

Appraisal in progress

Indication

Status: In progress

Substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.

Medicine details

Medicine name buprenorphine (Sixmo®)
Formulation 74.2 mg implant
Reference number 4262
Indication

As above

Company L. Molteni & C. dei Fratelli Alitti Società di Esercizio S.p.A.
BNF chapter Central nervous system
Submission type Full
Status In progress
NMG meeting date 05/01/2022
AWMSG meeting date 09/02/2022
Date of issue TBC